Retatrutide (LY3437943) is an investigational once-weekly injection from Eli Lilly that activates three metabolic receptors simultaneously — GIP, GLP-1, and glucagon — producing the highest average weight loss ever recorded in a Phase 3 clinical trial. In TRIUMPH-1 (May 2026), adults with obesity on the 12mg dose lost a mean of 28.3% of body weight at 80 weeks. At 104 weeks in a study extension, average weight loss reached 30.3%, a level that has historically required bariatric surgery to achieve pharmacologically. Retatrutide is not FDA-approved. NDA submission to the FDA is expected Q4 2026 to Q1 2027, with a regulatory decision projected in 2027 to 2028.
The Science Behind Retatrutide: Why Three Receptors Matter
To understand why retatrutide produces substantially more weight loss than current approved medications, it helps to understand what each of its three receptor mechanisms contributes — and why the combination is additive rather than simply cumulative.
GLP-1 receptor agonism is the shared mechanism with semaglutide (Wegovy, Ozempic). GLP-1 slows gastric emptying, suppresses appetite through hypothalamic signaling, and stimulates glucose-dependent insulin secretion. It is the foundational mechanism of the current GLP-1 drug class and responsible for the 10 to 15% average weight loss observed with semaglutide.
GIP receptor agonism is the mechanism that distinguishes tirzepatide (Zepbound, Mounjaro) from semaglutide. GIP acts synergistically with GLP-1 to amplify appetite suppression, improves insulin sensitivity in adipose tissue, and may increase the hypothalamic sensitivity to GLP-1 itself. Adding GIP to GLP-1 raised average weight loss from approximately 15% to approximately 20% in head-to-head comparison.
Glucagon receptor agonism is the new mechanism retatrutide adds beyond the dual agonist class. Glucagon stimulates thermogenesis in brown adipose tissue, increases hepatic fatty acid oxidation, and promotes lipolysis in white adipose tissue. In simpler terms: it increases the number of calories the body burns at rest. Combined with the appetite suppression from GLP-1 and GIP, the result is a simultaneous reduction in caloric intake and increase in caloric expenditure — a combination that has not previously been achieved in a single approved pharmacologic agent.
All efficacy and safety data cited in this article comes from Eli Lilly’s published Phase 2 trial (NEJM 2023) and Phase 3 TRIUMPH program press releases (2025 to 2026). Retatrutide cannot be prescribed as an approved therapy in the United States. Patients currently seeking pharmacologic weight loss have access to FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy). This article provides clinical context on an investigational drug approaching regulatory review.
TRIUMPH Program: Phase 3 Trial Results
Eli Lilly’s TRIUMPH program is the Phase 3 clinical development framework for retatrutide, comprising multiple trials across obesity, type 2 diabetes, cardiovascular disease, knee osteoarthritis, sleep apnea, and metabolic liver disease. Two major trials have reported topline results as of June 2026.
TRIUMPH-1 (May 2026) — the pivotal obesity trial
TRIUMPH-1 is the definitive efficacy trial, randomizing 2,339 adults with obesity or overweight and at least one weight-related comorbidity (but without type 2 diabetes) to retatrutide 4mg, 9mg, or 12mg, or placebo. The trial ran 80 weeks with a pre-specified 104-week extension. All three active doses met primary and key secondary endpoints.
Key results on the 12mg dose (the highest studied): mean weight reduction 28.3% (approximately 70.3 lbs) at 80 weeks. In the 104-week extension, mean weight reduction reached 30.3% (approximately 85 lbs). At the more tolerable 4mg dose, participants still achieved 19.0% average weight loss at 80 weeks with lower rates of discontinuation due to adverse events.
TRIUMPH-4 (December 2025) — obesity plus knee osteoarthritis
TRIUMPH-4 was the first Phase 3 readout, studying adults with obesity or overweight and knee osteoarthritis. The 12mg dose produced 28.7% mean body weight reduction at 68 weeks (approximately 71.2 lbs), with concurrent significant reductions in knee pain scores. This trial confirmed that the efficacy signal observed in Phase 2 replicates at Phase 3 scale and extends to relevant comorbidity populations.
Upcoming TRIUMPH readouts (2026)
TRIUMPH-2 (type 2 diabetes with obesity), TRIUMPH-3 (cardiovascular disease with obesity), and trials in sleep apnea and metabolic liver disease are expected to report in 2026. The TRANSCEND-T2D-1 trial, which reported June 2026, showed HbA1c reduction of 2.0% alongside 16.8% weight loss in a type 2 diabetes population, anchoring the diabetes programme alongside the obesity data.
Semaglutide (Wegovy, STEP-1): 14.9% at 68 weeks
Tirzepatide (Zepbound, SURMOUNT-1): 20.2% at 72 weeks
Retatrutide (TRIUMPH-1): 28.3% at 80 weeks; 30.3% at 104 weeks
Each generation has produced roughly 5 to 8 additional percentage points of weight loss. The jump from tirzepatide to retatrutide (approximately 8 percentage points at comparable timepoints) is the largest single step in this progression and the first to reach the efficacy range associated with bariatric surgery in a controlled pharmacologic trial.
How Retatrutide Compares to Current Approved Options
| Factor | Retatrutide | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon | GIP + GLP-1 | GLP-1 only |
| Mean weight loss (pivotal trial) | 28.3% at 80 wks | 20.2% at 72 wks | 14.9% at 68 wks |
| Patients achieving 30%+ weight loss | 45.3% at 80 wks (12mg) | Not reached at approved doses | Not reached at approved doses |
| Liver fat reduction | 86% reduction (Phase 2, 48 wks) | Significant (SURMOUNT-NASH) | Significant (STEP studies) |
| CV outcomes data | TRIUMPH-3 ongoing (2026) | SURPASS-CVOT ongoing | SELECT: 20% CV event reduction |
| FDA approval status | Investigational; NDA expected Q4 2026 to Q1 2027 | Approved 2023 (obesity) | Approved 2021 (obesity) |
| Availability | Clinical trials only (ClinicalTrials.gov NCT05929066) | Available by prescription | Available by prescription |
Safety Profile: What We Know and What Is Still Pending
The complete Phase 3 safety dataset for retatrutide will be presented at medical meetings and published in peer-reviewed journals following topline press release announcements. Current safety knowledge comes from Phase 2 published data and topline TRIUMPH summaries.
Shared GLP-1 class side effects
Retatrutide produces the gastrointestinal adverse effects common to the GLP-1 drug class: nausea, vomiting, diarrhea, and constipation. These occur most frequently during dose escalation and typically diminish at stable doses. The escalation protocol starts at 2mg weekly and increases in 4-week steps, following the same philosophy as tirzepatide’s ramp-up schedule to minimize GI burden.
Glucagon-specific considerations
The glucagon receptor agonism in retatrutide introduces monitoring requirements not present in semaglutide or tirzepatide. Glucagon is glycogenolytic, meaning it raises blood glucose, which is balanced by the GLP-1 and GIP insulin-sensitizing effects in the drug’s combined mechanism. Heart rate elevation has been observed with glucagon receptor activation and requires cardiovascular monitoring, particularly in higher-risk patients. The TRIUMPH-3 cardiovascular outcomes trial is the key data source for understanding retatrutide’s cardiovascular tolerability, with results anticipated in 2026 to 2027.
Dose-dependent tolerability
TRIUMPH-1 data showed that the 4mg dose produced lower discontinuation rates due to adverse events than the 12mg dose, while still achieving 19.0% average weight loss. This suggests a meaningful dose-response relationship in both efficacy and tolerability, giving prescribers flexibility to balance weight loss goals against individual patient tolerability — a clinical property comparable to tirzepatide’s multi-dose flexibility.
Any product marketed as retatrutide by online vendors, compounding pharmacies, or non-trial sources is not the Eli Lilly investigational compound and has not been evaluated by the FDA for safety, purity, or efficacy. Eli Lilly has not licensed retatrutide to any compounding pharmacy. The only legitimate access to retatrutide is through participation in the TRIUMPH clinical trial program via ClinicalTrials.gov (NCT05929066 and related studies). Patients interested in trial participation can contact Lilly’s Trial Information Center at 1-877-285-4559.
The Regulatory Pathway: Timeline to Approval
Retatrutide: Path to FDA Approval (Projected Timeline)
Projected based on Eli Lilly’s published trial schedule and standard FDA review timelines. Unexpected safety signals or regulatory requests for additional data could alter this projection.
Broader Clinical Applications: Beyond Obesity
The addition of glucagon receptor agonism gives retatrutide a broader metabolic footprint than current approved agents, positioning it for multiple indications that share underlying metabolic dysregulation.
Retatrutide Clinical Development: Conditions Under Study
What Patients Should Know Right Now
Retatrutide’s Phase 3 data confirms it will be a clinically meaningful advance when approved. For patients currently navigating weight loss therapy decisions, several practical points are worth understanding.
Current approved therapy remains the right choice for most patients now. Tirzepatide (Zepbound) averaging 20.2% weight loss and semaglutide (Wegovy) averaging 14.9% are both clinically effective, evidence-based, and available today. For patients with obesity-related cardiovascular risk, metabolic disease, or type 2 diabetes, the benefit of treating now rather than waiting 12 to 24 months for retatrutide access substantially outweighs any marginal additional weight loss that retatrutide might provide in the future.
Current therapy does not preclude future retatrutide access. Patients who initiate tirzepatide or semaglutide now can, if clinically appropriate, transition to retatrutide after it becomes approved and accessible. The drugs work through overlapping mechanisms, but the specific transition protocol (timing, dose relationships) will require clinical guidance at that point. Starting current therapy now and potentially transitioning later is a clinically sound strategy.
Watch for updates on TRIUMPH-2 and TRIUMPH-3. The diabetes population data (TRIUMPH-2) and cardiovascular outcomes data (TRIUMPH-3) expected in 2026 will be the most clinically significant remaining readouts. TRIUMPH-3’s cardiovascular event data will be particularly important for patients with prior cardiovascular events, as semaglutide’s SELECT trial result (20% CV event reduction) currently gives Wegovy a unique cardiovascular label that no other weight loss drug has matched.
For a complete overview of currently approved weight loss medications and how to choose between tirzepatide and semaglutide today, see our evidence-based comparison of tirzepatide vs semaglutide and our detailed guide on semaglutide for weight management: dosing, risks and expectations.
Get Evaluated for Current Weight Loss Therapy
Advanced TRT Clinic provides physician-supervised weight management via telemedicine including tirzepatide and semaglutide-based protocols with clinical oversight, lab coordination, and ongoing management. We track the retatrutide regulatory programme and will update our clinical offerings as new FDA-approved options become available. Availability varies by state.
